Using 7HP349 to help patients with solid tumors resistant to anti-PD-1 treatment
Official title: 7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors
Funded at 7 Hills Pharma, LLC · NIH-10931527 · Data updated 2026-11-12
This study is testing a new oral medication called 7HP349 to see if it can help boost the effectiveness of current cancer treatments for patients who haven't responded well to anti-PD-1 therapies, with the hope of improving results while keeping side effects low.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | 7 Hills Pharma, LLC NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $999,200 |
| NIH project number | 5R44CA285207-02 |
| Project ID | NIH-10931527 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors, particularly melanoma, who have shown resistance to anti-PD-1 therapies.
✕Less likely to help
Patients who do not have solid tumors or those who have not previously received anti-PD-1 treatment may not benefit from this research.
What this research studies
This research investigates the use of 7HP349, an oral medication designed to activate specific integrins that play a key role in immune response. The goal is to enhance the effectiveness of existing immunotherapies, particularly for patients who have developed resistance to anti-PD-1 treatments. By combining 7HP349 with standard therapies like ipilimumab and nivolumab, the researchers aim to improve patient outcomes while minimizing side effects. The study has already shown promising results in laboratory models and has progressed through early clinical trials.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with solid tumors who currently have limited choices due to resistance to existing therapies.
How similar studies have gone: Previous research has shown that enhancing T cell activity can improve responses to immunotherapy, suggesting that this approach may be promising.
Where this research is happening
-
7 Hills Pharma, LLC
Houston, United States Active
Researchers
- Principal investigator: Marathi, Upendra — 7 Hills Pharma, LLC
- Study coordinator: Marathi, Upendra
Related research
Other NIH-funded projects on the same topics.
-
Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors
A program uses mouse tumor models to identify promising drug candidates for children with sarcoma and other solid tumors.
-
Engineered CAR T immune cells targeting GPC3 for children's solid tumors
Engineered CAR T immune cells that produce IL-15 and IL-21 to better find and fight GPC3-positive solid tumors in children.
-
Boosting CAR T cell power in solid tumors by turning on transcription factors
A new research project tests whether turning on specific human transcription factors can make CAR T cells work better against solid tumors.
-
Engineering CD19 mimotopes to boost and broaden CD19-CAR T cell therapy
A patient-focused look at improving existing CD19-CAR T cell therapy so more people with blood cancers might benefit.
-
Radio-triggered CAR-T cells to better control solid tumors
A new approach uses radiation to turn on and guide CAR-T cells to fight solid tumors more effectively, potentially improving local and distant tumor control for patients with cancer.
-
Understanding how cell behavior changes drive breast cancer in 3D cultures
Researchers are studying how breast cells transition toward cancer using advanced 3D cultures and patient-derived samples to uncover important cell-state changes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.